You are here: Industry Insights > Ensovibep

News List

Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 WorldPharmaNews
January 13, 2022
Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19...
Novartis and Molecular Partners report positive topline data from phase-II study for Ensovibep ExpressPharma
January 11, 2022
The secondary endpoint of hospitalisation and/or ER visits related to COVID-19, or death showed an overall 78 per cent reduction in risk of events across Ensovibep arms compared to placebo.
Novartis and Molecular Partners commence Covid-19 treatment trial pharmaceutical-technology
May 31, 2021
Novartis and Molecular Partners have commenced Phase II/III EMPATHY clinical trial of a new DARPin therapeutic candidate, ensovibep (MP0420), to treat Covid-19.